M&A - Casdin Capital, LLC

Back to List of Mergers and Acquisitions

Form Type: SCHEDULE 13D/A

Filing Date: 2025-03-04

Corporate Action: Merger

Type: Update

Accession Number: 000091957425001773

Filing Summary: Casdin Capital, LLC and related entities increased their holdings in Standard BioTools Inc., currently owning 20.4% of the company's common stock. Significant transactions included the acquisition of Series B-1 Convertible Preferred Stock and loans, most notably a merger with SomaLogic, Inc. completed on January 5, 2024, which transitioned SomaLogic into a wholly owned subsidiary of Standard BioTools. Each SomaLogic share converted to 1.11 shares of Standard BioTools' stock, affecting outstanding equity awards. This filing updates previous disclosures regarding their investment and intentions, which include potential future activities with the company.

Document Link: View Document

Additional details:

Reporting Persons: Casdin Capital, LLC

Reporting Persons: Casdin Private Growth Equity Fund II, L.P.

Reporting Persons: Casdin Private Growth Equity Fund II GP, LLC

Reporting Persons: Casdin Partners Master Fund, L.P.

Reporting Persons: Casdin Partners GP, LLC

Reporting Persons: Eli Casdin

Beneficial Owner: 76,075,636

Ownership Percentage: 20.4

Company: Standard BioTools Inc.

Principal Office Address: 2 Tower Place, Suite 2000, South San Francisco, California 94080

Transaction Date: 2024-01-05

Merger Acquired Company: SomaLogic, Inc.

Exchange Ratio: 1.11

Term Loan Amount Casdin PMF: 8,750,000

Term Loan Amount Casdin PGEII: 3,750,000

Comments

No comments yet. Be the first to comment!